Dec 10, 2019 SOURCE: BusinessWire

FEops Awarded Euro 3.2 Million Grant From EU

FEops, a leader in personalized predictive planning for structural heart interventions, has been awarded a grant of Euro 3.2 million from the European Innovation Council (EIC) accelerator programme.

“We are very proud to receive this grant, given the fierce competition. This ranks us now in the top 4% of all European deep tech start-ups applying for the highly competitive EIC Accelerator programme! Over 1850 applications were submitted to this funding round of the EIC programme and only 75 projects were selected for funding by the European Commission” said Isabelle Decroos, CFO FEops

The Euro 3.2 million grant will accelerate the clinical evidence gathering and business implementation of FEops HEARTguide predictive pre-operative planning for transcatheter structural heart interventions on a worldwide scale.

FEops HEARTguide^TM, which received CE mark and approval for the Canadian market earlier this year, is a one-in-its-kind procedure planning environment for structural heart interventions that provides physicians unique insights to evaluate device sizing and positioning pre-operatively using novel computational modeling and simulation technology. The current release includes workflows for transcatheter aortic valve implantation (TAVI) and left atrial appendage occlusion (LAAO) procedures.

“This important milestone could only be reached by the continuous and high commitment from all our team members, the physicians who believe in our technology and other partners who support us in this journey. The EIC grant will not only boost our clinical and business implementation, but will also enable us to extend our device certifications” said Matthieu De Beule, co-founder and CEO FEops.

FEops HEARTguide^TM cloud-based procedure planning environment uses advanced personalized computational modeling and simulation to provide clinicians and medical device manufacturers with first-ever insights into the interaction between transcatheter structural heart devices and specific patient anatomy – preoperatively. The current release includes TAVI and LAAO workflows. Such insights have the power to accelerate research and development of novel device-based solutions, as well as ultimately help to improve clinical outcomes in real-world hospital settings.

About FEops

Privately held FEops, headquartered in Gent, Belgium, is a leader in personalized predictive planning for structural heart interventions. In September 2017, FEops announced that it closed a 6 million euros financing, led by Valiance, and joined by existing investors Capricorn Venture Partners and PMV.

www.feops.com